Phase III Trial Failures: Costly But Preventable

August 23, 2017

This article, published in Applied Clinical Trials, by Dr. Alberto Grignolo, Corporate Vice President, Parexel Consulting and Dr. Sy Pretorius, Chief Scientific Officer, examines reasons for the high failure rate of Phase III studies and innovative approaches companies can take to mitigate risk.
 

Previous Flipbook
Understanding Regulatory Requirements in Today’s Accelerated Approval Environment
Understanding Regulatory Requirements in Today’s Accelerated Approval Environment

Even for drugs that may never reach market, Accelerated Pathways can help companies deploy resources more e...

Next Flipbook
Regulatory Handbook: Data Integrity: FDA And Global Regulatory Guidance
Regulatory Handbook: Data Integrity: FDA And Global Regulatory Guidance

Learn the newest trends and regulatory changes as we guide you through FDA and global regulations, guidance...